drugset / Trial / NCT06178874

Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia

NCT06178874

Completed 90 enrolled Ain Shams University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The role of ultralong insulin in the control of the blood glucose level in diabetic patients is well known, the current study will discuss the role of ultralong insulin in controlling of hyperglycaemia in critical illness defined as failure or impending failure of an organ

Timeline

Start
2023-12-01
Primary completion
2024-05-25
Completion
2024-06-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator insulin degludec Protein / enzyme biologic 0.2 iu/kg Subcutaneous
Comparator insulin glargine Protein / enzyme biologic 0.2 iu/kg Subcutaneous
Comparator Insulin regular Unknown Intravenous